Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:05:54.031Z.
Consensus retrieved: 2026-10-06T09:18:39.130Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:05:54.031Z.
Quote observation: 2026-10-06T17:05:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Forward PE Ratio (N/A) = Dated Quote Price ($16.58) / Consensus Forward EPS ($-3.42)
FORWARD PE RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.09B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.09B | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.09B | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 40.05 |
| STAAR Surgical Company (STAA)vs › | $1.11B | 76.72 |
| OPKO Health, Inc. (OPK)vs › | $1.12B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 8.61 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $16.58, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.42 | $-3.61 – $-3.34 | 10 | n/m |
| 2027-12-31 | $-3.62 | $-3.89 – $-3.36 | 9 | n/m |
| 2028-12-31 | $-3.42 | $-4.56 – $-1.52 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
